With multiple clinical stage product candidates in Phase 2 and Phase 3 development, each from a new class of potential intranasal therapies that we call pherines, each has a differentiated mechanism ...

Aquestive Therapeutics (AQST – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram ...

AstraZeneca (AZ) and Amgen have shared positive results from a late-stage study of Tezspire (tezepelumab) in patients with ...

On Saturday, Denmark-based ALK entered into a strategic license agreement with ARS Pharmaceuticals, Inc. (NASDAQ:SPRY). The agreement grants ALK exclusive global rights to the neffy adrenaline ...

ARS Pharmaceuticals (SPRY) announced a licensing agreement with ALK-Abello A/S (AKBLF), that provides ALK exclusive rights to commercialize ...

Becker's asked pharmacy executives from hospitals and health systems across the U. S. to share their team or system's biggest achievement this year.